Lyell Immunopharma announces new data from trial of rondecabtagene autoleucel

Lyell Immunopharma (LYEL) announced new clinical and translational data from the ongoing clinical trial of rondecabtagene autoleucel in patients with large B-cell lymphoma, LBCL, which were presented today in two oral presentations at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition. As of the data cutoff date of September 5, 2025, ronde-cel continued to demonstrate robust clinical responses with a manageable safety profile appropriate for outpatient administration. A 93% overall response rate, a 76% complete response rate, and median progression-free survival of 18 months were reported for patients with relapsed and/or refractory LBCL in the third- or later-line setting. Patients evaluated in the second-line setting achieved an 83% overall response rate and a 61% complete response rate, and 70% of patients with a complete response remained in complete response at 6 months or longer.